Evidence map›Paper›PMID 42294229›Full record

ArticleACS omega2026

An Antibacterial "Drug-Drug" Cocrystal of Trimethoprim with Sulfathiazole Achieving Synchronized Dual-Drug Release and Pharmacokinetics.

Wen-Hao Li, Xiao-Han Sun, Xin Chen, Shun-Hu Gao, Fu-Ying Li, Han Mo, Xin-Yu Hu, Xue-Kun Wang, Fang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wen-Hao LiSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Xiao-Han SunSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Xin ChenSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Shun-Hu GaoSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Fu-Ying LiSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Han MoSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Xin-Yu HuSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Xue-Kun WangSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.
Fang LiuSchool of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng University, Liaocheng, Shandong 252059, PR China.ORCID https://orcid.org/0000-0002-5225-725X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving synchronized release and absorption of multiple active pharmaceutical ingredients with disparate properties has long been a critical challenge in the development of combination formulations. Multidrug cocrystals offer a promising strategy to address this issue. As a classic antibacterial combination, trimethoprim (TMP) and sulfathiazole (STZ) are widely used in conventional therapy. This study reports a drug-drug cocrystal composed of the two ingredients. The TMP-STZ cocrystal was characterized by SCXRD, PXRD, DSC-TG, and IR spectroscopy. Furthermore, its hygroscopicity, solubility, dissolution, and in vivo pharmacokinetics were systematically evaluated. The results demonstrate that the pronounced initial solubility difference between TMP and STZ was effectively balanced through cocrystallization, leading to consistent dissolution rates. These in vitro modifications enabled synchronized and enhanced pharmacokinetic profiles for the two drugs in vivo. The 110 min T

Identifiers

PMID42294229
PMCPMC13261454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.